Amazon Inc. shares retreated in early March trading as broader market risk-off sentiment from escalating Middle East conflict pressured tech names, compounding investor caution over the company’s massive $200 billion capital expenditure plan for 2026 focused on AI infrastructure and cloud expansion.

The e-commerce and cloud computing giant’s stock (NASDAQ: AMZN) traded around $206-207 in mid-morning sessions on March 3, 2026, down about 1.5-2% from the prior close of $210.00 on Feb. 27. Pre-market activity showed levels near $205-206, reflecting a pullback from recent ranges of $203-211. The stock has hovered 18-20% below its 52-week high of $258.60 reached in November 2025, with a low of $161.38 earlier in the year. Year-to-date performance remains positive but tempered by February’s volatility, including a nine-day losing streak in mid-February that erased over $450 billion in market value before a brief rebound.

Amazon’s latest earnings, released Feb. 5, 2026, for the fourth quarter of 2025, delivered strong results but sparked mixed reactions. Full-year 2025 net sales reached approximately $717 billion, surpassing Walmart’s $713 billion for the first time in annual revenue and marking a milestone in retail dominance. Fourth-quarter revenue hit record levels, with AWS contributing $35.6 billion — up 24% year-over-year — its fastest growth in 13 quarters, driven by surging demand for AI workloads.

Operating income expanded significantly, with AWS delivering $12.5 billion in the quarter. CEO Andy Jassy highlighted AWS’s “top-to-bottom AI stack” as a key differentiator, enabling customers to run AI alongside existing applications and data. Advertising revenue also accelerated, supporting profitability across segments.

The outlook, however, weighed on sentiment. Amazon guided for about $200 billion in 2026 capital expenditures — far exceeding consensus estimates around $146 billion — primarily for data centers, custom chips like Trainium, networking and AI infrastructure. Jassy described the spending as fueling “seminal opportunities” in AI, robotics, chips and low-Earth orbit satellites, with expectations of strong long-term returns on invested capital.

Guidance for the first quarter of 2026 projected net sales between $173.5 billion and $178.5 billion (11-15% growth) and operating income of $16.5-21.5 billion, incorporating higher costs from projects like Amazon Leo and international pricing investments.

A major boost came from a landmark Feb. 27 announcement: Amazon’s $50 billion investment in OpenAI as part of the startup’s $110 billion funding round, valuing OpenAI at $840 billion. The deal expands an existing AWS agreement by $100 billion over eight years, with OpenAI committing to 2 gigawatts of Trainium capacity (including next-gen Trainium4 in 2027) and gaining exclusive third-party distribution for its Frontier enterprise agent platform. OpenAI will also help develop customized AI models for Amazon’s consumer businesses.

Analysts view the partnership as positioning AWS strongly in the AI race, potentially adding $17 billion annually in revenue (about 11% of expected 2026 AWS totals) and accelerating cloud adoption. UBS projects AWS growth surging to 38% in 2026 from 19% in 2025, with mid-30% momentum possibly extending into 2027.

Despite the positives, shares have faced pressure from elevated spending concerns, potential delays in ROI from AI buildouts and broader tech sector dynamics. Free cash flow projections turned negative for 2026 in some estimates due to capex intensity, though management stresses long-term value.

Market capitalization stands near $2.2-2.3 trillion, with a forward P/E around 29 — near a 10-year low and seen as attractive by bulls. Analysts maintain a consensus “Buy” rating, with average price targets around $280-282, implying 30-35% upside from recent levels.

Amazon continues diversifying: retail innovations in India via seller fee cuts, quick commerce investments and robotics advancements. North America operating margins improved to 9% in Q4 2025, while international segments showed progress.

As geopolitical risks and macro uncertainties persist, Amazon’s blend of e-commerce scale, AWS dominance and aggressive AI positioning keeps it central to tech narratives. Upcoming data on AI adoption, capex execution and Q1 results (expected late April) will guide near-term trajectory.

Investors weighing the heavy spending against accelerating cloud/AI momentum see Amazon as a high-conviction long-term play, even amid short-term volatility.

The UK can be a very beautiful place. This nation is laden with spots and locations with historical, architectural and aesthetic value, many of which fall under the category of conservation areas.

These are areas that local planning authorities determine to be of a certain interest and value, and then take careful steps to preserve them in terms of character. There are over 10,000 conservation areas in the UK, as designated by the Civic Amenities Act, and those living in them have to be conscious of specific building regulations.

Homeowners should make sure that they are comprehensively aware of any rules before they get to work on their home. For those trying to liven up their entryways, there are some essential regulations for installing a new front door in a conservation area. This article will explore these regulations, so you can feel more confident knowing what to do if you’re interested in some new contemporary front doors.

Understanding Article 4

Conservation area regulations aren’t on the same level as those for Listed Buildings; however, they are still much stricter than in the average home. The most common legal consideration to make is understanding Article 4 Directions. Article 4 can essentially strip away your “Permitted Development” rights, meaning you need full blown planning permission, even for minor changes, like front doors (even as granularly as a paint job).

Without Article 4 in place, you can generally replace a door without specified permission, as long as you don’t change the style too significantly.

Solution. Check with your local council on their website for an “Article 4 map” or appraisal tool.

Standard new front door building regulations for all homeowners

Every front door needs to meet the minimum standards set in the country, whether your home is impacted by the Listed Buildings and Conservation Areas Act 1990 or not. It’s always good practice to make sure that your door meets standards for:

Thermal performance. Replacement doors need to hit a minimum U-value of 1.4W/m²K in 2026.

Safety glass. Low glass panels on doors (below 1500mm) need to be made from toughened glass.

Accessibility. Homes built after 1999 cannot replace level, flat entry thresholds with stepped ones as it restricts disabled access (not generally relevant to conservation areas).

Outside of conservation area building regulations, there are plenty of considerations all homeowners should keep in mind.

Materials & design considerations for conservation areas

A lot of the charm and appeal of a building in a conservation area comes from the materials and designs used on the property. Generally, you should follow the golden rule of “like-for-like”, meaning the front of the house should use doors with the same materials as before.

Composite and uPVC doors are often prohibited from the front of the home.

It’s also important to match any stained glass or leaded patterns on the original doors.

High-gloss modern glazing is likely to be rejected in favour of “heritage” glass with a more slimline profile.

Modern hardware and shiny chrome elements might be discouraged, with era-suitable brass and iron often more compliant with conservation.

Consulting with your council

If you’re sitting wondering “Is my home in a conservation area?” or “Can I get around Article 4?”, you should get in touch with your council. They should be able to provide you with all the essential information you need about your property and your rights to it, ensuring you maintain a standard of character in the area while still upgrading your home.

Staying in the know is essential if you are curious about conservation areas, as a wrong move could end up with you in conflict with the local area.

This article was written by

Follow

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Johnson & Johnson shares advanced to near their 52-week peak in recent trading, outperforming a broader market pullback driven by escalating Middle East tensions and oil price surges, as investors sought refuge in the healthcare giant’s stable earnings, robust dividend and diversified portfolio.

The company’s stock (NYSE: JNJ) closed at $248.43 on Feb. 27, 2026, up $4.96 or 2.04% from the previous session, on elevated volume of over 16.4 million shares — about 70% above average. In early March 3 trading, shares hovered around $249.24, up modestly in a session where futures indicated pressure from geopolitical risks. The rally pushed JNJ within striking distance of its intraday high of $248.94 from late February, marking a 52-week range from $141.50 to nearly $252. Year-to-date gains exceed 10%, with the stock up about 38% over the past six months despite ongoing talc litigation headwinds.

Johnson & Johnson’s resilience stems from its January 2026 earnings report for the fourth quarter and full year 2025. The company posted strong results, with full-year sales growth supporting an upbeat 2026 outlook. Q4 revenue reached approximately $24.28 billion, while adjusted EPS came in at levels that beat some expectations despite a slight miss in certain views ($2.46 vs. consensus near $2.47). Innovative Medicine (pharmaceuticals) and MedTech segments drove performance, with key products like Darzalex and Tremfya showing robust sales.

For 2026, J&J guided reported sales to $99.5 billion to $100.5 billion (midpoint $100.5 billion, up about 6.7%), and adjusted EPS of $11.43 to $11.63 (midpoint $11.53, up 6.9%). The forecast exceeded Wall Street estimates even after factoring in impacts from drug pricing agreements with the Trump administration and potential tariffs on medical devices, estimated at hundreds of millions. Analysts praised the guidance as conservative yet achievable, highlighting oncology pipeline strength and biosimilar competition offsets.

The company maintains a market capitalization approaching $600 billion, with a forward P/E ratio around 22-23 — viewed as attractive for a blue-chip healthcare name. The quarterly dividend of $1.30 per share (annualized $5.20, yield about 2.09%) remains a draw for income investors. The ex-dividend date was Feb. 24, 2026, with payment on March 10.

Recent pipeline advancements bolster confidence. In late February, J&J reported promising early Phase 1b results for pasritamig (a bispecific T-cell engager) combined with docetaxel in advanced prostate cancer, showing deep PSA reductions and manageable safety. On Feb. 24, the company submitted a supplemental Biologics License Application to the FDA for IMAAVY (nipocalimab) as the first treatment for warm autoimmune hemolytic anemia (wAIHA). Upcoming presentations include the Barclays Global Healthcare Conference on March 10 and TD Cowen on March 3.

Talc litigation continues to cast a shadow, though the stock’s performance suggests investors are pricing in manageable risk. As of early 2026, the multidistrict litigation includes over 67,000 plaintiffs alleging ovarian cancer or mesothelioma from talc products. Recent verdicts include a $250,000 award in a Philadelphia case in February for a deceased user’s family, and larger prior awards like $1.5 billion in a 2025 mesothelioma trial (under appeal). J&J insists its products are safe and asbestos-free, pursuing appeals and settlement discussions. No global resolution has emerged post-bankruptcy attempts.

Analysts maintain a consensus “Moderate Buy” rating, with average price targets around $233 (some as high as $262), implying modest upside or stability from current levels. Firms like Morgan Stanley upgraded to Buy with a $262 target in January, citing improving 2026 prospects.

In a market facing geopolitical uncertainty — with oil surging on Iran-related developments — JNJ’s defensive characteristics shine. Healthcare stocks often hold up during risk-off periods, and J&J’s low beta, consistent cash flow and innovation in high-growth areas like oncology position it well.

The company continues executing its post-Kenvue separation strategy, focusing on Innovative Medicine and MedTech for sustained growth. With next earnings expected around April 14, 2026, investors will watch for updates on pipeline momentum, litigation developments and macro impacts.

Johnson & Johnson’s blend of stability, yield and growth potential keeps it a core holding for many portfolios amid broader volatility.